Christopher Healy
Cardiovascular Disease · Indianapolis, INNPI 1033352877
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 70.1% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $100,029, more than ten times the $3,645 reported in 2019. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 616 payments — averaging $338.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$146K
- Boston Scientific$37K
- Medtronic$11K
- Abbott$6K
- Biotronik Inc.$6K
- Novartis$280
- plus $3K from 30 others
What the payments were for
- Consulting fees$89,35543%
- Speaking & faculty fees$62,28530%
- Travel & lodging$38,04518%
- Food & beverage$18,9619%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 117 | $146,298 |
| Boston Scientific | 163 | $36,588 |
| Medtronic(2 entities) | 83 | $11,045 |
| Abbott | 82 | $6,189 |
| Biotronik Inc. | 29 | $5,657 |
| Novartis | 14 | $280 |
| Pfizer | 15 | $247 |
| Inari Medical, Inc. | 2 | $231 |
| AstraZeneca | 11 | $211 |
| Novo Nordisk | 9 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $169 |
| Bayer | 10 | $165 |
| Amgen | 9 | $146 |
| Cardiofocus, Inc. | 3 | $145 |
| Johnson & Johnson | 8 | $135 |
| Kestra Medical Technology Services, Inc. | 6 | $122 |
| Penumbra, Inc. | 4 | $110 |
| Terumo Medical Corporation | 4 | $89 |
| Boehringer Ingelheim | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $69 |
| Stryker | 1 | $61 |
| Altathera Pharmaceuticals LLC | 2 | $37 |
| Scpharmaceuticals Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Atricure, Inc. | 1 | $23 |
| Angiodynamics, Inc. | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Elutia, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$120,147
- (5028) IGT Devices Systems Undivided$11,800
- GENERAL - THERAPIES$8,783
- (9124) LM Undivided$4,659
- AVEIR$3,627
- Spectranetics Undiv$3,575
- AFFERA MAPPING SYSTEM$1,616
- (8328) Image Guided Therapy Devices _ Therapy$1,410
- Trilogy 100$975
- TightRail$900
- ENSITE$784
- BioMonitor$780
- GENERAL EP$742
- Rivacor 7 DR-T$636
- Edora 8 DR-T$636
- Solia$636
- Acticor 7 VR-T DX$636
- IGT Devices Und$603
- Micra$572
- US Und$515
How this compares
$208,646 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $680,695 |
| XareltoRivaroxaban | 70 | $75,494 |
| Dofetilide | 135 | $15,544 |
| Amiodarone Hcl | 267 | $3,362 |
| Flecainide Acetate | 88 | $3,197 |
| Verapamil SrVerapamil Hcl | 50 | $2,708 |
| SotalolSotalol Hcl | 120 | $2,705 |
| Metoprolol Succinate | 183 | $2,101 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 77 | $1,522 |
| Verapamil ErVerapamil Hcl | 31 | $1,040 |
| Warfarin Sodium | 72 | $740 |
| Potassium Chloride | 25 | $216 |
| Digoxin | 11 | $215 |
| Carvedilol | 32 | $210 |
| Metoprolol Tartrate | 37 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $247 | $680,695612 claims |
| Johnson & JohnsonXarelto | $135 | $75,49470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.